stockmarketproxy
/
GILDNasdaq SEC EDGAR

GILEAD SCIENCES, INC.

Biological Products, (No Diagnostic Substances)·FOSTER CITY, CA·FY end 12/31·CIK 882095
OverviewFinancialsCompensationGovernanceInsidersFilings

Named Executive Officers

FY 2025
ExecutiveSalaryStockOptionsBonus / Inc.OtherTotal
Daniel P. O’DayChairman and Chief Executive Officer
$1.8M$15.2M$4.5M$4.8M$2.1M$28.4M
Dietmar BergerM.D., Ph.D. Chief Medical Officer
$969.2K$7.0M$1.0M$4.6M$350.3K$13.9M
Johanna MercierChief Commercial and Corporate Affairs Officer
$1.2M$4.6M$1.3M$2.2M$103.0K$9.3M
Andrew D. DickinsonChief Financial Officer
$1.1M$4.3M$1.3M$2.0M$71.0K$8.8M

CEO pay mix

Daniel P. O’Day · FY 2025
Total$28.4M
Stock awards$15.2M54%
Performance bonus$4.8M17%
Salary$1.8M6%
Other$6.6M23%

Performance vs. pay

TSR % vs. CEO comp actually paid · 5 fiscal years · Item 402(v) disclosure
FY
TSR
CEO comp
FY21
+30%
$31M
FY22
+61%
$55M
FY23
+57%
$15M
FY24
+87%
$45M
FY25
+155%
$63M

CEO comp · median worker · ratio — multi-year trend

Need at least two fiscal years of proxy data to draw the trend line. The ingestion worker will populate prior-year proxies as it processes them.